TPD52L2

Across TCGA pan-cancer cohorts, TPD52L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPD52L2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TPD52L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TPD52L2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

CCRCC, COAD, and LSCC are the cancer types where TPD52L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.559	0.946	<.001	57	view →
COAD	DFS	Median	II,III,IV	1.000	0.912	.012	24	view →
LSCC	OS	Tertile	II,III,IV	0.656	0.981	.001	22	view →
LUAD	OS	Quartile	II,III,IV	0.401	1.000	.010	18	view →
PDAC	OS	Tertile	All	0.372	0.603	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPD52L2–CCRCC (DFS)

Open the CCRCC breakdown →